11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Rivaroxaban Accord

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Rivaroxaban

Rivaroxaban

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Roberti R, Iannone LF, Palleria C, Curcio A, Rossi M, Sciacqua A et al. Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Front Pharmacol. 2021;12(0):684638.

  2. Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169(0):123-127.

  3. Beyer-Westendorf J, Tittl L, Bistervels I, Middeldorp S, Schaefer C, Paulus W et al. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. Lancet Haematol. 2020;7(12):e884-e891.

  4. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy - a systematic review. J Perinat Med. 2022; aop.

  5. Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105:117-26.

  6. Søgaard M, Skjøth F, Nielsen PB, Beyer-Westendorf J, Larsen TB. First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. Am J Med. 2021.

  1. Roberti R, Iannone LF, Palleria C, Curcio A, Rossi M, Sciacqua A et al. Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Front Pharmacol. 2021;12(0):684638.
  2. Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169(0):123-127.
  3. Beyer-Westendorf J, Tittl L, Bistervels I, Middeldorp S, Schaefer C, Paulus W et al. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. Lancet Haematol. 2020;7(12):e884-e891.
  4. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy - a systematic review. J Perinat Med. 2022; aop.
  5. Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105:117-26.
  6. Søgaard M, Skjøth F, Nielsen PB, Beyer-Westendorf J, Larsen TB. First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. Am J Med. 2021.